Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium

Core Insights - Astellas Pharma is set to present new data on potential treatments for pancreatic and gastric/gastroesophageal junction (G/GEJ) cancer at the 2026 ASCO GI Cancers Symposium, highlighting advancements in precision oncology and the company's commitment to improving patient outcomes [1][2]. Company Developments - Astellas will showcase results from the Phase 2 ILUSTRO study, which evaluates the efficacy of zolbetuximab in combination with chemotherapy and immunotherapy for treating claudin 18.2-positive, HER2-negative, locally advanced or metastatic G/GEJ cancer [1][3]. - The company is also advancing ASP3082 (setidegrasib), a targeted protein degrader for KRAS G12D mutations, currently in Phase 1 trials for pancreatic cancer [1][4]. Presentation Details - Key presentations at the ASCO GI 2026 include: - Oral presentation of the Phase 2 ILUSTRO trial results on January 8, 2026, focusing on zolbetuximab plus mFOLFOX6 and nivolumab [3]. - Poster presentations on various topics, including biomarker testing and treatment selection for gastric or GEJ adenocarcinoma [3][4]. Product Information - VYLOY (zolbetuximab) is a first-in-class monoclonal antibody targeting claudin 18.2, currently the only approved treatment for CLDN18.2-positive (HER2-negative) gastric or GEJ cancer in several regions, including the U.S. and Europe [7][8]. - ASP3082 (setidegrasib) targets KRAS G12D mutations, which are present in approximately 40% of pancreatic ductal adenocarcinomas, and is being evaluated for its safety and efficacy in clinical trials [12].